As filed with the Securities and Exchange Commission on September 17, 2025 Registration No. 333-286850 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Safe & Green Holdings Corp. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 5030 95-4463937 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...

Group 1 - Solventum (SOLV) is one of 974 companies in the Medical group, which is currently ranked 7 within the Zacks Sector Rank [2] - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook with a 6.1% increase in the consensus estimate for full-year earnings over the past quarter [3] - Year-to-date, Solventum has gained approximately 10.8%, outperforming the Medical sector, which has returned an average of -2.7% [4] Group 2 - Solventum is part of the Medical Services industry, which consists of 58 companies and is currently ranked 99 in the Zacks Industry Rank, with a year-to-date loss of about 2.6% [5] - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector with a return of 51.7% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has a total of 485 stocks and is currently ranked 105, with a year-to-date increase of 2.8% [6]

Group 1: Stock Performance - CVS Health's stock decreased by 1.98% to $73.50, underperforming the S&P 500 which gained 0.47% [1] - Over the past month, CVS Health's shares increased by 9.3%, outperforming the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% [1] Group 2: Earnings Projections - CVS Health is expected to report earnings of $1.36 per share, reflecting a year-over-year growth of 24.77% [2] - Revenue is projected at $97.96 billion, an increase of 2.65% from the same quarter last year [2] Group 3: Fiscal Year Estimates - For the fiscal year, earnings are estimated at $6.34 per share, indicating a growth of 16.97% [3] - Revenue for the fiscal year is projected to be $391.11 billion, representing a 4.91% increase from the previous year [3] Group 4: Analyst Estimates and Confidence - Recent adjustments to analyst estimates for CVS Health indicate changing near-term business trends, with positive revisions suggesting confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks CVS Health at 3 (Hold) [6] Group 5: Valuation Metrics - CVS Health has a Forward P/E ratio of 11.82, which is lower than the industry's Forward P/E of 16.7, indicating a valuation discount [7] - The PEG ratio for CVS Health is 0.83, compared to the Medical Services industry's average PEG ratio of 1.5 [7] Group 6: Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 148, placing it in the bottom 41% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Teladoc's stock closed at $7.49, down 3.97%, underperforming the S&P 500's daily gain of 0.3% [1] - Over the past month, Teladoc shares appreciated by 13.54%, outperforming the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09% [1] Earnings Projections - The upcoming earnings release projects an earnings per share (EPS) of -$0.24, a 26.32% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $625.56 million, down 2.33% from the year-ago period [2] Full Year Estimates - For the full year, the Zacks Consensus Estimates project an EPS of -$1.17 and revenue of $2.52 billion, reflecting changes of +80.07% and -1.82% respectively from the preceding year [3] - Recent changes to analyst estimates indicate a shifting business landscape, with positive revisions suggesting optimism about the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which assesses estimate changes, currently ranks Teladoc as 3 (Hold) [5] - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 146, placing it in the bottom 41% of over 250 industries [6]

Albion Enterprise VCT PLC Interim Management Statement LEI Code: 213800OVSRDHRJBMO720 Introduction I present Albion Enterprise VCT PLC (the “Company”)’s interim management statement for the period from 1 April 2025 to 30 June 2025. Performance and dividends The Company's unaudited net asset value (“NAV”) on 30 June 2025 was £277.3 million or 115.72 pence per share (excluding treasury shares), a decrease of 0.50 pence per share (0.4%) since 31 March 2025. After accounting for the first dividend for the year ...

Group 1: Company Performance - CVS Health shares have increased by 17.1% over the past month, reaching a 52-week high of $73.23, and have gained 63% since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical Services industry, which saw gains of -2.3% and 0.7% respectively [1] - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters, with the latest EPS reported at $1.81 against a consensus estimate of $1.47, and revenue exceeding estimates by 5.54% [2] Group 2: Earnings Projections - For the current fiscal year, CVS Health is expected to report earnings of $6.32 per share on revenues of $390.17 million, reflecting a 16.61% increase in EPS and a 4.66% increase in revenues [3] - For the next fiscal year, earnings are projected to be $7.14 per share on revenues of $408.98 million, indicating a year-over-year change of 12.94% in EPS and 4.82% in revenues [3] Group 3: Valuation Metrics - CVS Health has a Value Score of A, with Growth and Momentum Scores of C and F respectively, resulting in a VGM Score of B, indicating it is a suitable choice for value investors [6][8] - The stock trades at 11.6X current fiscal year EPS estimates, below the peer industry average of 17.7X, and at 8.1X trailing cash flow compared to the peer group's average of 10.5X, with a PEG ratio of 0.81 [7] Group 4: Zacks Rank - CVS Health holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend, making it a favorable option for investors seeking stocks with strong potential [8] Group 5: Industry Comparison - CVS Health remains a strong choice within the Medical Services industry, which ranks in the bottom 64% of all industries, but still shows promising tailwinds alongside peers like Progyny, Inc. [9][11]

Financial Performance - The Group achieved a consolidated pro-forma turnover of RON 1.57 billion in H1 2025, a 20.3% increase compared to H1 2024 [19] - Pro-forma EBITDA increased by 21.2% to RON 234.2 million, with a margin of 16.1% [34] - IFRS Revenues recorded a solid 20% increase, with 16.2% driven by organic growth [50] - Net cash from operating activities declined by 41% compared to the same period last year [60] Acquisitions and Investments - The Group finalized the acquisition of Routine Med Group in Tulcea in February [21] - A majority stake in All Clinic in the Republic of Moldova was acquired in March [21] - The acquisition of Medstar Clinic Group in Cluj-Napoca was announced in June, with 2024 revenues of approximately RON 32 million [22] - The company launched the first AI assistant integrated into its mobile app [25] - The company enhanced its diagnostic infrastructure with the 2nd automated laboratory line in the Group, with an investment of over EUR 2 million [26] - The company acquired the Illumina sequencing technology with an initial investment of EUR 3 million [27] Operational KPIs - Hospitals revenue increased by 37.8% to RON 437.787 million [50] - Clinics revenue increased by 20.3% to RON 586.623 million [50] - Laboratories revenue increased by 18.4% to RON 172.790 million [50]

Core Insights - The article compares two Medical Services stocks, Cencora (COR) and Medpace (MEDP), to determine which is more attractive for value investors [1] Valuation Metrics - Both COR and MEDP currently have a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3] - COR has a forward P/E ratio of 18.30, while MEDP has a forward P/E of 33.85 [5] - COR's PEG ratio is 1.38, compared to MEDP's PEG ratio of 2.98, suggesting COR is expected to grow earnings at a more favorable rate [5] - COR has a P/B ratio of 25.49, while MEDP's P/B ratio is significantly higher at 77.18 [6] - Based on these valuation metrics, COR holds a Value grade of A, whereas MEDP has a Value grade of D, indicating that COR is currently the superior value option [6]

Market Overview - A-shares experienced a volatile trading day following a significant increase on August 25, with the Shanghai Composite Index closing down 0.39% at 3868.38 points, while the Shenzhen Component Index rose 0.26% [1] - The market saw strong performance in sectors such as poultry, pork, gaming, chemicals, and consumer electronics, while sectors like medical services and rare earth permanent magnets faced declines [1] Sector Performance - The pork concept stocks remained strong, with Aonong Bio (603363) hitting the daily limit [1] - The gaming sector was active, with 37 Interactive Entertainment (002555) also reaching the daily limit [1] - The chemical sector showed continued activity, with Baiao Chemical (603360), Yuntu Holdings (002539), and Haiyang Technology (603382) all hitting the daily limit [1] - Consumer electronics stocks were lively, with companies like GoerTek (002241) reaching the daily limit [1] - In contrast, the medical services sector led the declines, with Sunlight Nuohuo and Hite Bio (300683) among the biggest losers [1] - The rare earth permanent magnet sector also faced downward pressure, with AVIC TianDa and Baosteel (600010) leading the declines [1] Huawei Concept Stocks - Huawei concept stocks collectively rose, with the Huawei Kunpeng Index and Huawei Harmony Index both increasing over 2% [2] - Notable performers included Junyi Digital (301172) which achieved a 20% limit up, and Aerospace Hongtu which surged over 10% [2] - The Harmony Index saw stocks like Tuwei Information (002261) hitting the daily limit, along with other companies such as Runhe Software (300339) and Changshan Beiming (000158) following suit [2] Upcoming Developments - On August 25, during the Harmony Intelligent Travel autumn product launch, SAIC and Huawei announced the pre-sale of their first model under the "Shangjie" brand, the H5 [2] - Huawei is set to release a new AI SSD product on August 27, which may significantly impact the existing landscape of China's AI storage market [2]

Core Points - The Ohio Medical Alliance (OMA) has experienced a cybersecurity incident affecting the personal information of hundreds of thousands of patients and employees [1] - The data breach potentially compromised various types of sensitive information, including names, dates of birth, home addresses, social security numbers, and medical records [1] Company Investigation - Lynch Carpenter, LLP is investigating claims against OMA related to the data breach and is offering potential compensation to affected individuals [2] About Lynch Carpenter - Lynch Carpenter is a national class action law firm with a focus on data privacy matters, having represented millions of clients over more than a decade [3]